Regional variation of postjunctional alpha-adrenoceptor responses in the developing renal vascular bed of sheep.
Postjunctional alpha 1- and alpha 2-adrenoceptor vasoconstrictor responses were evaluated in isolated segments of main renal artery, segmental renal artery, and renal vein from fetal (130-138 d of gestation; term 145 d), newborn (3-15 d age), and nonpregnant adult sheep. Vascular rings were mounted at their optimal resting tension and responses to phenylephrine (alpha 1-adrenoceptor agonist) and guanabenz and UK14304 (both alpha 2-adrenoceptor agonists) were determined. Optimal resting tension increases with development in the main renal artery, segmental renal artery, and renal vein of sheep. Arterial vessels develop more isometric tension to alpha 1-adrenoceptor stimulation than to alpha 2-adrenoceptor stimulation, whereas venous segments develop similar isometric tension to alpha 1- and alpha 2-adrenoceptor stimulation. The segmental renal artery develops more isometric tension to alpha 2-adrenoceptor stimulation than the main renal artery. No large developmental differences exist among vessels in the sensitivity (concentration required for half maximal response, ED50) to alpha-adrenoceptor stimulation except for the renal vein with alpha 2-adrenoceptor stimulation. Maximum isometric tension corrected for vessel cross-sectional area decreases with age for all vessels with both alpha 1- and alpha 2-adrenoceptor stimulation. These findings may reflect developmental differences in receptor number and affinity or differences in vascular smooth muscle function. In addition, these data suggest that whereas both alpha 1- and alpha 2-adrenoceptors mediate vasoconstriction in the renal circulation, they may do so at different sites.
Matherne
G P
GP
Department of Pediatrics, University of Iowa College of Medicine, Iowa City 52242.
Nakamura
K T
KT
Alden
B M
BM
Rusch
N J
NJ
Robillard
J E
JE
D000367:Age Factors; D000818:Animals; D000831:Animals, Newborn / Q000254:growth & development / Q000502:physiology*; D000068438:Brimonidine Tartrate; D005333:Fetus / Q000502:physiology*; D006143:Guanabenz / Q000494:pharmacology; D007537:Isometric Contraction; D007668:Kidney / Q000098:blood supply* / Q000196:embryology / Q000502:physiology; D009119:Muscle Contraction; D009131:Muscle, Smooth, Vascular / Q000502:physiology*; D010656:Phenylephrine / Q000494:pharmacology; D011810:Quinoxalines / Q000494:pharmacology; D011942:Receptors, Adrenergic, alpha / Q000494:pharmacology*; D012077:Renal Artery / Q000196:embryology / Q000502:physiology; D012082:Renal Veins / Q000196:embryology / Q000502:physiology; D012756:Sheep; D014661:Vasoconstriction
D011810:Quinoxalines; D011942:Receptors, Adrenergic, alpha; D010656:Phenylephrine; D000068438:Brimonidine Tartrate; D006143:Guanabenz